Karyopharm Therapeutics (KPTI) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free KPTI Stock Alerts $0.97 +0.02 (+2.11%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 1:45 PM | prnewswire.comKaryopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesMay 29, 2024 | prnewswire.comKaryopharm to Participate at the Jefferies Global Healthcare ConferenceMay 23, 2024 | investorplace.comThe Next Novavax? 3 Biopharma Stocks to Buy Before They BoomMay 15, 2024 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by AnalystsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and three have issued a buy ratinMay 10, 2024 | seekingalpha.comKPTI Karyopharm Therapeutics Inc.May 10, 2024 | markets.businessinsider.comBuy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic OutlookMay 10, 2024 | finance.yahoo.comKaryopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | markets.businessinsider.comOptimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical TrialsMay 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Karyopharm Therapeutics in a report on Thursday.May 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | finance.yahoo.comQ1 2024 Karyopharm Therapeutics Inc Earnings CallMay 8, 2024 | finanznachrichten.deKaryopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 8, 2024 | finance.yahoo.comKaryopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed ReviewMay 8, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. Q1 Loss increases, but beats estimatesMay 8, 2024 | prnewswire.comKaryopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 8, 2024 | investorplace.comKPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comKaryopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 8, 2024 | prnewswire.comKaryopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029May 3, 2024 | marketbeat.comKaryopharm Therapeutics (KPTI) Scheduled to Post Earnings on WednesdayKaryopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 2, 2024 | prnewswire.comKaryopharm to Report First Quarter 2024 Financial Results on May 8, 2024May 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | prnewswire.comKaryopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingApril 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 15, 2024 | finance.yahoo.comKPTI Apr 2024 5.000 callMarch 15, 2024 | finance.yahoo.comKPTI Apr 2024 1.500 putMarch 14, 2024 | businesswire.comOnco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO ® (selinexor)March 6, 2024 | finance.yahoo.comKaryopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesMarch 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)March 5, 2024 | finance.yahoo.comInsider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...March 2, 2024 | seekingalpha.comKaryopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPSKaryopharm Therapeutics (NASDAQ:KPTI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $33.75 million during the quarter, compared to analyst estimates of $33.50 million. During the same period in the prior year, the company earned ($0.43) earnings per share.March 1, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have received a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three haveMarch 1, 2024 | marketbeat.comBrokers Offer Predictions for Karyopharm Therapeutics Inc.'s FY2025 Earnings (NASDAQ:KPTI)Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at Leerink Partnrs issued their FY2025 earnings per share estimates for Karyopharm Therapeutics in a research note issued to investors on Thursday, February 29th. Leerink Partnrs analyst J. Chang expects that the company wiMarch 1, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $8.00 at HC WainwrightHC Wainwright decreased their price objective on shares of Karyopharm Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday.February 29, 2024 | fool.comKaryopharm Therapeutics (KPTI) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comQ4 2023 Karyopharm Therapeutics Inc Earnings CallFebruary 29, 2024 | finanznachrichten.deKaryopharm Therapeutics Inc.: Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 29, 2024 | msn.comKaryopharm Therapeutics GAAP EPS of -$0.36 misses by $0.07, revenue of $33.7M beats by $0.08MFebruary 29, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. Q4 Loss misses estimatesFebruary 29, 2024 | finance.yahoo.comKaryopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 28, 2024 | benzinga.comKaryopharm Therapeutics's Earnings: A PreviewFebruary 27, 2024 | finance.yahoo.comKPTI Mar 2024 1.000 putFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)February 25, 2024 | ca.finance.yahoo.comKPTI Mar 2024 1.500 callFebruary 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 23, 2024 | marketbeat.comKaryopharm Therapeutics (KPTI) to Release Quarterly Earnings on ThursdayKaryopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Thursday, February 29, Zacks reports.February 23, 2024 | benzinga.comKaryopharm Therapeutics Stock (NASDAQ:KPTI) Earnings Dates and Earning Calls Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Do This Before July 30 2024 To Claim Trump’s Gift (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. KPTI Media Mentions By Week KPTI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPTI News Sentiment▼0.620.76▲Average Medical News Sentiment KPTI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPTI Articles This Week▼32▲KPTI Articles Average Week Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BioXcel Therapeutics News Today Aerovate Therapeutics News Today Corbus Pharmaceuticals News Today Oculis News Today KalVista Pharmaceuticals News Today PepGen News Today Travere Therapeutics News Today Applied Therapeutics News Today Annexon News Today Erasca News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPTI) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.